Safety profile of 
ICLUSIG (ponatinib) in Ph+ ALL

Explore ICLUSIG safety profile in Philadelphia chromosome-positive Acute Lymphoblastic Leukemia

Comparable safety vs imatinib + chemotherapy in newly diagnosed Ph+ ALL by utilizing optimized dosing1,2

ICLUSIG safety in Ph+ ALL is supported by two pivotal trials. PhALLCON, the head-to-head phase 3 trial vs imatinib in newly diagnosed Ph+ ALL, with both regimens given in combination with chemotherapy, established that ICLUSIG + chemotherapy had a comparable safety profile to imatinib + chemotherapy by utilizing optimized dosing.1,2 PACE provides safety data for ICLUSIG monotherapy in patients whose disease is resistant or intolerant to a prior TKI or who have the T315I mutation.1

PhALLCON trial safety profile of ICLUSIG in Ph+ ALL

PACE trial safety profile of ICLUSIG in Ph+ ALL

Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor

Ph+ ALL Patient Profiles

""

Ph+ ALL Dosing Guide

""

Ph+ ALL Resources and Support

""